OncoMatch/Clinical Trials/NCT06644781
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Is NCT06644781 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Ifinatamab deruxtecan and Docetaxel for esophageal squamous cell carcinoma.
Treatment: Ifinatamab deruxtecan · Docetaxel · Paclitaxel · Irinotecan hydrochloride (HCl) — This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Esophageal Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — unresectable advanced or metastatic ESCC
disease progression post a platinum-based chemotherapy
Must have received: immune checkpoint inhibitor — unresectable advanced or metastatic ESCC
disease progression post...an ICI treatment per global or local guidelines
Cannot have received: B7-H3 targeted agent (orlotamab, enoblituzumab, I-DXd)
prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd
Cannot have received: topoisomerase inhibitor
received any topoisomerase inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Providence Medical Foundation · Fullerton, California
- Henry Ford Health System · Detroit, Michigan
- Baptist Cancer Center · Memphis, Tennessee
- SCRI Oncology Partners · Nashville, Tennessee
- John Peter Smith Hospital · Fort Worth, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06644781 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior B7-H3 targeted agent, topoisomerase inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages